Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structure-activity relationships of dimeric PPAR agonists.

Per Sauerberg1, John P Mogensen, Lone Jeppesen

  • 1Novo Nordisk A/S, Novo Nordisk Park, 2760 Måløv, Denmark. psa@novonordisk.com

Bioorganic & Medicinal Chemistry Letters
|February 17, 2005
PubMed
Summary

Researchers designed dimeric Peroxisome Proliferator-Activated Receptor (PPAR) agonists, finding they retained or increased PPARgamma potency. This dimeric approach offers a way to fine-tune PPAR subtype selectivity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interaction between Paracetamol Glucuronide and a Glucose-Sensitive Insulin Molecule (NNC2215): Increased Risk of Hypoglycemia.

ACS pharmacology & translational science·2026
Same author

Structural and functional characterization of a hyperthermostable single-stranded DNA-binding protein from a hot spring metagenome.

Protein science : a publication of the Protein Society·2026
Same author

Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH.

Alimentary pharmacology & therapeutics·2025
Same author

NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control.

Cancer immunology research·2025
Same author

Glucose-sensitive insulin with attenuation of hypoglycaemia.

Nature·2024
Same author

Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis.

eLife·2024

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Peroxisome Proliferator-Activated Receptors (PPARs) are nuclear receptors regulating gene expression.
  • PPAR agonists are used in treating metabolic diseases, but subtype selectivity is crucial.
  • Developing novel agonists with improved potency and selectivity remains an active research area.

Purpose of the Study:

  • To design and evaluate a series of novel dimeric PPAR agonists.
  • To investigate the structure-activity relationships (SAR) of these dimeric ligands.
  • To explore the potential of dimeric agonists for fine-tuning PPAR subtype selectivity.

Main Methods:

  • In vitro testing of designed dimeric ligands for PPAR activity.
  • Structure-activity relationship (SAR) analysis.

Related Experiment Videos

  • Molecular modeling to explain observed potency.

    • Main Results:

    • Dimeric ligands, including those with common or full dimeric structures, demonstrated retained or enhanced PPARgamma potency.
    • The study identified specific structural features influencing PPAR activity.
    • Molecular modeling provided insights into the binding interactions and potency of PPARgamma agonists.

    Conclusions:

    • The dimeric agonist concept is a viable strategy for developing potent PPAR ligands.
    • Dimeric PPAR agonists offer a promising avenue for achieving fine-tuned subtype selectivity.
    • Further exploration of dimeric PPAR agonists could lead to improved therapeutic agents.